International Stem Cell Corp. (OTCMKTS:ISCO) Short Interest Update

International Stem Cell Corp. (OTCMKTS:ISCO) was the target of a large drop in short interest during the month of June. As of June 30th, there was short interest totaling 6,699 shares, a drop of 51.1% from the June 15th total of 13,705 shares. Based on an average trading volume of 7,053 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.3% of the company’s shares are sold short.

International Stem Cell Price Performance

Shares of International Stem Cell stock opened at $0.21 on Friday. International Stem Cell has a one year low of $0.12 and a one year high of $0.23. The business’s 50 day simple moving average is $0.17 and its two-hundred day simple moving average is $0.16. The stock has a market capitalization of $1.71 million, a P/E ratio of -3.56 and a beta of -0.01.

International Stem Cell (OTCMKTS:ISCO) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share for the quarter. The firm had revenue of $2.32 million during the quarter.

International Stem Cell Company Profile

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.